OLD Republic International Corp lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 3.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,491,000 shares of the biopharmaceutical company’s stock after selling 47,500 shares during the quarter. Pfizer makes up about 1.8% of OLD Republic International Corp’s investment portfolio, making the stock its 13th largest position. OLD Republic International Corp owned approximately 0.09% of Pfizer worth $53,229,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the second quarter worth $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer during the second quarter worth $103,000. D. Scott Neal Inc. grew its stake in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Herndon Capital Management LLC acquired a new stake in shares of Pfizer during the second quarter worth $120,000. Finally, Lipe & Dalton grew its stake in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares during the period. Institutional investors own 69.74% of the company’s stock.
Pfizer Inc. (NYSE PFE) opened at $36.54 on Friday. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $217,800.00, a PE ratio of 22.42, a price-to-earnings-growth ratio of 2.44 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the firm earned $0.61 earnings per share. The company’s revenue was up .9% on a year-over-year basis. equities research analysts predict that Pfizer Inc. will post 2.59 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.72%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s payout ratio is presently 78.53%.
Pfizer declared that its board has authorized a stock repurchase program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.
A number of brokerages recently commented on PFE. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price objective for the company. in a research note on Monday. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Tuesday, October 3rd. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Finally, Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $38.83.
In other news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock valued at $1,065,220 over the last ninety days. 0.06% of the stock is owned by insiders.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.